|
A
new era in hormone-refractory
prostate cancer
A call for subspecialist caregivers to
collaborate in the provision of newer
chemotherapy combinations
Fred Saad, MD, FRCSC et al
Facing
cancer costs
Sorting out public and private funding
options that maximize value, equity
and individual rights
Brent Zanke, MD, PhD, FRCPC; Pamela
C. Spencer, BSocSc LLB, MHSc; Tony Culyer, BSc, CBE, BA, DEcon,
FRSA, FRCP, FMedSci; Christopher J. Longo, MSc, PhD; Maurice McGregor,
MB, BCh, MD, MRCP
Advocacy to advance
cancer care policy
How the National Cancer Leadership
Forum helped secure funding for the
Canadian Cancer Strategy
Esther Green, RN, MScT, Beth Kapusta,
Pat Kelly
Symptom identification
and management
Report of a pilot project to assess
patients’ symptoms and provide
rapid referral
Deborah Dudgeon, MD, FRCPC; Janice
P. Van Dijk, RN, MHSc, MSc and Anne Smith, BSc, MBChB, MRCP(UK),FRC
The role of taxanes in the
treatment of breast cancer
New approaches to tailor therapy and
minimize toxicities
Susan Dent, BSc, MD, FRCPC and Xinni
Song, BSc, MD, FRCPC
Funded by an educational grant from
Abraxis Oncology
|
Essential
reading: research
updates and commentaries
Review of important clinical trial data
recently presented at the 48th Annual
Meeting of the American Society of
Hematology
With commentaries by Tony Reiman,
MD, FRCPC and A. Robert Turner, MD, FRCPC
acute lymphoblastic leukemia
acute myeloid leukemia
multiple myeloma
Review of important clinical trial data
recently presented at the 29th Annual
San Antonio Breast Cancer Symposium
With commentaries by Danuta
Balicki, MD, PhD, FRCPC, FACP; Debjani Grenier, MD, FRCPC; Hagen
Kennecke, MD, MHA, FRCPC; Joseph Ragaz, MD,
FRCPC; Daniel Rayson, MD, FRCPC and Sunil Verma, MD, MSEd, FRPCP
Adjuvant chemotherapy for
early breast cancer
Metastatic breast cancer
Breast cancer epidemiology
Hormonal therapy for
breast cancer
Breast cancer prevention
Breast cancer in
premenopausal women
Biological markers and
chemotherapy
Combined hormonal and
targeted therapy
Risk in T1a–bN0, HER2+
breast cancer
cancer Stem cells and
resistance to treatment
Professional meetings roster
Your calendar dates for essential conferences and symposia
New drugs and indications
A review of recent cancer therapy approvals in Canada and the U.S.
|
